Zymeworks Inc. (NASDAQ:ZYME) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET
Company Participants
Jack Spinks - Head of Investor Relations
Neil Klompas - President & COO
Kenneth Galbraith - Chair and CEO
Neil Josephson - CMO
Paul Moore - Chief Scientific Officer
Conference Call Participants
Stephen Willey - Stifel
Charles Zhu - Guggenheim Securities
Hosni Mubarak - Citi
Gena Wang - Barclays
James Shin - Wells Fargo
Amy Li - Jefferies
Operator
Ladies and gentlemen, thank you for standing by. This is conference operator. Welcome to Zymeworks Third Quarter 2022 Results Conference Call and Webcast. As a reminder, all participants are in a listen only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]
I would now like to turn the conference over to Jack Spinks, Head of Investor Relations at Zymeworks. Jack, please go ahead.
Jack Spinks
Good afternoon, and welcome everyone. My name is Jack Spinks, Head of Investor Relations here at Zymeworks. Today, we will discuss our third quarter 2022 financial results, as well as provide an update to our ongoing business.
Before we begin, I would like to remind you that we will be making a number of forward-looking statements during this call, including statements that relate to the implementation of our strategic priorities, development plans and timing, anticipated therapeutic effects and commercial potential of our current and future product candidates, expected regulatory interactions, anticipated data releases and timing thereof, expected financial performance and future financial position, our ability to execute new collaborations and partnerships and receive milestones from existing arrangements and other information that is not historical information. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC.
Later in this call, Neil Klompas, our President and Chief Operating Officer will be discussing our financial results, including certain adjusted non-GAAP measures. A description of our adjusted non GAAP measures and a reconciliation to the most directly comparable financial results as determined in accordance with GAAP are described in detail in our press release, which is available on our website at www.zymeworks.com under the Investor Relations tab. As a reminder, the audio and slides in this call will also be available on the Zymeworks' website later today.